Renal tumors: Diagnostic and prognostic biomarkers

American Journal of Surgical Pathology

Volumn 37, Issue 10, 2013, Pages 1518-1531

  Tan, Puay Hoon ^a   Cheng, Liang ^b   Rioux Leclercq, Nathalie ^g   Merino, Maria J ^c   Netto, George ^d   Reuter, Victor E ^e   Shen, Steven S ^f   Grignon, David J ^b   Montironi, Rodolfo ^h   Egevad, Lars ⁱ   Srigley, John R ^j   Delahunt, Brett ^k   Moch, Holger ^l   Abraham, Anila ^m   Adeniran, Adebowale ^m   Ahmed, Khalid ^m   Al Ahmadie, Hikmat ^m   Algaba, Ferran ^m   Allan, Robert ^m   Amin, Mahul ^m   Argani, Pedram ^m   Axcrona, Ulrika ^m   Barry, Marc ^m   Baydar, Dilek ^m   Bégin, Louis ^m   Berney, Dan ^m   Bethwaite, Peter ^m   Billis, Athanase ^m   Birbe, Ruth ^m   Bonsib, Stephen ^m   Bostwick, David ^m   Brimo, Fadi ^m   Cathro, Helen ^m   Chen, Ying Bei ^m   Cheville, John ^m   Cho, Yong Mee ^m   Chuang, Ai Ying ^m   Cohen, Cynthia ^m   Crist, Henry ^m   Delprado, Warick ^m   Deng, Fang Ming ^m   Epstein, Jonathan ^m   Evans, Andrew ^m   Fadare, Oluwole ^m   Fajardo, Daniel ^m   Falzarano, Sara ^m   Fine, Samson ^m   Fleming, Stewart ^m   Fridman, Eddie ^m   Furusato, Bungo ^m   Ganji, Masoud ^m   Ghayouri, Masoumeh ^m   Giannico, Giovanna ^m   Gokden, Neriman ^m   Griffiths, David ^m   Gupta, Nilesh ^m   Hameed, Omar ^m   Hes, Ondrej ^m   Hirsch, Michelle ^m   Huang, Jiaoti ^m   Huang, Wei ^m   Van De Kaa, Christina Hulsbergen ^m   Humphrey, Peter ^m   Hussein, Sundus ^m   Iczkowski, Kenneth ^m   Jimenez, Rafael ^m   Jones, Edward ^m   Jufe, Laura Irene ^m   Kench, James ^m   Kida, Masatoshi ^m   Kristiansen, Glen ^m   Kunju, Lakshmi Priya ^m   Lane, Zhaoli ^m   Latour, Mathieu ^m   Lewin, Claudio ^m   Lie, Kathrine ^m   Lloreta, Josep ^m   Loftus, Barbara ^m   Lopez Beltran, Antonio ^m   Maclean, Fiona ^m   Magi Galluzzi, Cristina ^m   Martignoni, Guido ^m   McHale, Teresa ^m   McKenney, Jesse ^m   Miller, Rose ^m   Miyamoto, Hiroshi ^m   Murphy, Hedwig ^m   Nacey, John ^m   Nazeer, Tipu ^m   Nesi, Gabriella ^m   Nichols, Peter ^m   O'Donnell, Marie ^m   Olgac, Semra ^m   Orozco, Roberto ^m   Osunkoya, Adeboye ^m   Ozagari, Aysim ^m   Pan, Chin Chen ^m   Parwani, Anil ^m   Perry Keene, Joanna ^m   Petraki, Constantina ^m   Picken, Maria ^m   Pyda Karwicka, Maria ^m   Rezaei, Katayoon ^m   Robinson, Brian ^m   Rohan, Stephen ^m   Ronchetti, Ruben ^m   Russell, Laurie ^m   Samaratunga, Hemamali ^m   Scarpelli, Marina ^m   Shabaik, Ahmed ^m   Shah, Rajal ^m   Shanks, Jonathan ^m   Shevchuk, Maria ^m   Sibony, Mathilde ^m   Srinivasan, Bhuvana ^m   Susani, Martin ^m   Suzigan, Sueli ^m   Sweet, Joan ^m   Takahashi, Hiroyuki ^m   Tamboli, Pheroze ^m   Tickoo, Satish ^m   Trias, Isabel ^m   Trpkov, Kiril ^m   True, Larry ^m   Tsuzuki, Toyonori ^m   Vakar Lopez, Funda ^m   Van Der Kwast, Theo ^m   Wang, Cheng ^m   Warren, Anne ^m   Yao, Jorge ^m   Yilmaz, Asli ^m   Zhao, Jin ^m   Zhou, Ming ^m   Zynger, Debra ^m   more..

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j MCMASTER UNIVERSITY   (Canada)

^k UNIVERSITY OF OTAGO   (New Zealand)

^l UNIVERSITY OF ZURICH   (Switzerland)

^m NONE

more..

Author keywords

CK7; Immunohistochemistry; International Society of Urological Pathology; Pax 2; Pax 8; Renal cell carcinoma; Translocation carcinoma

Indexed keywords

EID: 84900393064     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318299f12e     Document Type: Article

References (81)

1. Delahunt B, Egevad L, Montironi R, et al. International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization. Am J Surg Pathol. 2013.
2. Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med. 2011;135:92-109.
3. Skinnider BF, Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005;22: 51-68.
4. Eble JN, Sauter G, Epstein JI, et al. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours. Lyon: IARC Press; 2004:10-43.
5. Tickoo SK, Reuter VE. Differential diagnosis of renal tumors with papillary architecture. Adv Anat Pathol. 2011;18:120-132.
6. Sangoi AR, Karamchandani J, Kim J, et al. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol. 2010;17:377-393.
7. Martignoni G, Brunelli M, Gobbo S, et al. Role of molecular markers in diagnosis and prognosis of renal cell carcinoma. Anal Quant Cytol Histol. 2007;29:41-49.
8. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35:678-686.
9. Sharma SG, Gokden M, McKenney JK, et al. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol. 2010;18:494-498.
10. Ozcan A, Zhai Q, Javed R, et al. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin. Arch Pathol Lab Med. 2010;134:1121-1129.
11. Olgac S, Hutchinson B, Tickoo SK, et al. Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol. 2006;19:218-224.
12. Lapinski JE, Chen L, Zhou M. Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: utility of immunohistochemical markers. Appl Immunohistochem Mol Morphol. 2010;18:414-421.
13. Pan CC, Chen PC, Tsay SH, et al. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol. 2005;13: 347-352.
14. Wang HY, Mills SE. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma. Am J Surg Pathol. 2005;29:640-646.
15. Martignoni G, Pea M, Brunelli M, et al. CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol. 2004;17: 1455-1463.
16. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210.
17. Boysen G, Bausch-Fluck D, Thoma CR, et al. Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia. 2012;14:535-546.
18. Stillebroer AB, Mulders PF, Boerman OC, et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010;58:75-83.
19. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008;123:395-400.
20. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med. 2005;25:247-257.
21. Strojan Flezar M, Gutnik H, Jeruc J, et al. Typing of renal tumors by morphological and immunocytochemical evaluation of fine needle aspirates. Virchows Arch. 2011;459:607-614.
22. Al-Ahmadie HA, Alden D, Fine SW, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35: 949-961.
23. Mete O, van der Kwast TH. Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intraabdominal neoplasms. Arch Pathol Lab Med. 2011;135:665-670.
24. Azabdaftari G, Alroy J, Banner BF, et al. S100 protein expression distinguishes metanephric adenomas from other renal neoplasms. Pathol Res Pract. 2008;204:719-723.
25. Mete O, Kapran Y, Gulluoglu MG, et al. Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas. Virchows Arch. 2010;456:515-521.
26. Reuter VE, Tickoo SK. Differential diagnosis of renal tumours with clear cell histology. Pathology. 2010;42:374-383.
27. Takehara K, Koga S, Nishikido M, et al. Breast cancer metastatic to the kidney. Anticancer Res. 1999;19:5571-5573.
28. Salem Y, Pagliaro LC, Manyak MJ. Primary small noncleaved cell lymphoma of kidney. Urology. 1993;42:331-335.
29. Davis RI, Corson JM. Renal metastases from well differentiated follicular thyroid carcinoma: a case report with light and electron microscopic findings. Cancer. 1979;43:265-268.
30. Wasco MJ, Pu RT. Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration. Diagn Cytopathol. 2008;36:568-573.
31. Weinbreck N, Marie B, Bressenot A, et al. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining. Am J Surg Pathol. 2008;32:1051-1059.
32. Ingold B, Wild PJ, Nocito A, et al. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology. 2008;52:674-681.
33. Jung SM, Kuo TT. Immunoreactivity of CD10 and inhibin alpha in differentiating hemangioblastoma of central nervous system from metastatic clear cell renal cell carcinoma. Mod Pathol. 2005;18: 788-794.
34. Rivera AL, Takei H, Zhai J, et al. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma. Neuropathology. 2010;30:580-585.
35. Aydin H, Young RH, Ronnett BM, et al. Clear cell papillary cystadenoma of the epididymis and mesosalpinx: immunohistochemical differentiation from metastatic clear cell renal cell carcinoma. Am J Surg Pathol. 2005;29:520-523.
36. Mertz KD, Demichelis F, Sboner A, et al. Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. Int J Cancer. 2008;123: 569-576.
37. Abrahams NA, MacLennan GT, Khoury JD, et al. Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology. 2004;45:593-602.
38. Bostwick DG, Cheng L. Urologic Surgical Pathology. 2nd ed. Missouri: Mosby-Elsevier; 2008:78-171.
39. Liu L, Qian J, Singh H, et al. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med. 2007;131:1290-1297.
40. Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48: 207-217.
41. Tickoo SK, Amin MB, Zarbo RJ. Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining. Am J Surg Pathol. 1998;22:419-424.
42. Cochand-Priollet B, Molinie V, Bougaran J, et al. Renal chromophobe cell carcinoma and oncocytoma. A comparative morphologic, histochemical, and immunohistochemical study of 124 cases. Arch Pathol Lab Med. 1997;121:1081-1086.
43. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29: 747-754.
44. Leroy X, Moukassa D, Copin MC, et al. Utility of cytokeratin 7 for distinguishing chromophobe renal cell carcinoma from renal oncocytoma. Eur Urol. 2000;37:484-487.
45. Garcia E, Li M. Caveolin-1 immunohistochemical analysis in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Am J Clin Pathol. 2006;125:392-398.
46. Huang W, Kanehira K, Drew S, et al. Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study. Appl Immunohistochem Mol Morphol. 2009;17:12-17.
47. Adley BP, Papavero V, Sugimura J, et al. Diagnostic value of cytokeratin 7 and parvalbumin in differentiating chromophobe renal cell carcinoma from renal oncocytoma. Anal Quant Cytol Histol. 2006;28:228-236.
48. Carvalho JC, Wasco MJ, Kunju LP, et al. Cluster analysis of immunohistochemical profiles delineates CK7, vimentin, S100A1 and C-kit (CD117) as an optimal panel in the differential diagnosis of renal oncocytoma from its mimics. Histopathology. 2011;58:169-179.
49. Eichelberg C, Junker K, Ljungberg B, et al. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009;55:851-863.
50. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539-542.
51. Pawlowski R, Muhl SM, Sulser T, et al. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer. 2013;132:E11-E17.
52. Lau LC, Tan PH, Chong TW, et al. Cytogenetic alterations in renal tumors: a study of 38 Southeast Asian patients. Cancer Genet Cytogenet. 2007;175:1-7.
53. Brunelli M, Delahunt B, Gobbo S, et al. Diagnostic usefulness of fluorescent cytogenetics in differentiating chromophobe renal cell carcinoma from renal oncocytoma: a validation study combining metaphase and interphase analyses. Am J Clin Pathol. 2010;133: 116-126.
54. Antonelli A, Portesi E, Cozzoli A, et al. The collecting duct carcinoma of the kidney: a cytogenetical study. Eur Urol. 2003;43: 680-685.
55. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34: 1295-1303.
56. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42:369-373.
57. Inamura K, Fujiwara M, Togashi Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012;36:35-42.
58. Argani P, Netto GJ, Parwani AV. Papillary renal cell carcinoma with low-grade spindle cell foci: a mimic of mucinous tubular and spindle cell carcinoma. Am J Surg Pathol. 2008;32:1353-1359.
59. Shen SS, Ro JY, Tamboli P, et al. Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. Ann Diagn Pathol. 2007;11:13-21.
60. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol. 2008;32:1239-1245.
61. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol. 2010;34:1608-1621.
62. Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol. 2011;24:1207-1220.
63. Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol. 2008;21:1-6.
64. Hes O, Brunelli M, Michal M, et al. Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Ann Diagn Pathol. 2006;10:133-139.
65. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer. 2005;5:57.
66. Rechsteiner MP, von Teichman A, Nowicka A, et al. VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: identification of potential driver and passenger mutations. Cancer Res. 2011;71:5500-5511.
67. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem. 2005;51:494-503.
68. Kroeze SG, Bijenhof AM, Bosch JL, et al. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Cancer Biomark. 2010;7:261-268.
69. Di Napoli A, Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer. 2009;115:2290-2297.
70. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
71. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
72. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
73. Pena C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res. 2010;16:4853-4863.
74. Tang PA, Vickers MM, Heng DY. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. Hematol Oncol Clin North Am. 2011;25:871-891.
75. Choueiri TK, Regan MM, Rosenberg JE, et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106: 772-778.
76. Bhatia S, Thompson JA. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Ther. 2009;26:55-67.
77. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714-3721.
78. Cho IC, Chung J. Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol. 2012;53:217-228.
79. Tostain J, Li G, Gentil-Perret A, et al. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer. 2010;46:3141-3148.
80. Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134:873-879.
81. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.